Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Drug Profile

Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Alternative Names: 7-Azaindole inhibitors; SGX 393; SGX 70393; SGX-70430

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator SGX Pharmaceuticals
  • Developer Novartis; SGX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic myeloid leukaemia

Most Recent Events

  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly
  • 30 Jun 2008 SGX Pharmaceuticals files an IND application with the US FDA for SGX 393
  • 11 Dec 2007 Pharmacodynamics data from a preclinical trial presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top